Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 299 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers

Oral Contraceptive Pills Compared to Vaginal Rings

NCT00357526
Conditions
Pregnancy
Interventions
OCPs, vaginal ring
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 21 Years · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
San Francisco, California
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
Interventions
Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-Prandial Liver Glucose Metabolism in PCOS

NCT03041129
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
oral glucose tolerance test, MRI of liver
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Prune Consumption and Bone Health in Young Women Using Hormonal Contraceptives

NCT04785131
Conditions
Osteoporosis Risk
Interventions
Prune
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Diego, California
Conditions
Polycystic Ovary Syndrome
Interventions
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Traumatic Brain Injury
Interventions
Blood/saliva sampling
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA

NCT02859337
Conditions
Obesity, Contraception
Interventions
UPA-ECx1, UPA-ECx2
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Conditions
Oral Contraceptive Pill Adherence
Interventions
Text messaging reminders
Behavioral
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
14 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Heart Failure
Interventions
Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Beverly Hills, California • Lake Forest, California • Santa Maria, California + 17 more
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Metabolic Syndrome, Polycystic Ovary Syndrome
Interventions
wheat dextrin, Oral Contraceptives, Low-Dose, Maltodextrin
Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy
Interventions
Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational Accepts healthy volunteers

Non-intrusive Detection of Temporary Neurologic Impairment by Opioids

NCT05489601
Conditions
Neurologic Impairment by Opioids
Interventions
Oxycodone
Drug
Lead sponsor
Zxerex Corporation
Industry
Eligibility
21 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

NCT01178125
Conditions
Contraception, Female Contraception
Interventions
DR-102
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,858 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
52
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348
Conditions
Primary Ovarian Insufficiency
Interventions
Hormone Replacement Therapy, Combined Oral Contraceptives
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Emergency Contraception
Interventions
Copper IUD, Levonorgestrel IUD
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Recruiting Phase 4 Interventional Accepts healthy volunteers

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

NCT05674513
Conditions
Contraceptive Usage
Interventions
Ulipristal acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Contraception
Interventions
Household Visits, Small Groups
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years and older
Enrollment
2,898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Colchicine With an Oral Contraceptive

NCT01040845
Conditions
Pharmacokinetics
Interventions
Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine)
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect on Primary Dysmenorrhea

NCT00909857
Conditions
Primary Dysmenorrhea
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova), Placebo Match to SH T00658ID, Placebo Match to SH D593B
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 50 Years · Female only
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Hialeah, Florida + 7 more